Duska, L. R., Banda, K., Oaknin, A., Ribrag, V., Martin, A. G., Lakhani, N. J., Lee, J., Tewari, A., Banerjee, S. N., Barretina-Ginesta, M., Boni, V., Brahmi, M., Eberst, L., Kim, J. H., Colombo, N., Lorusso, D., Faulhaber, N., Kann, L., Thakur, A., Drescher, C. (2025). Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with
            <i>ARID1A</i>
            -mutated ovarian clear cell carcinoma or endometrial carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3102